Argonaut Manufacturing Services opens custom controls & standards facility

The CMO has designed the new service to alleviate manufacturing challenges associated with positive controls and nucleic acid templates
Argonaut Manufacturing Services, a contract manufacturing organization for Life Science, Diagnostic, and BioPharma markets, has launched a new service offering to support the growing need for custom controls, standards and verification panels.
Formulating and filling these products will be performed at a new standalone facility in Carlsbad, California.
The company said the site has been designed to alleviate many of the concerns expressed with the manufacturing challenges associated with positive controls and nucleic acid templates.
Controls and standards are used regularly by innovators to verify instruments, reagents, and diagnostic tests to ensure standard operating procedures (SOPs) are followed properly for patient samples.
The Custom Molecular Controls and Standards service provides organizations focusing on diagnostics for the regulated markets and RUO (research use only) assays, a complete solution for their commercial products with Argonaut and controls that match the same quality standards that Argonaut Manufacturing Services provides.
“This service offering has been widely requested by our clients in every market from Point of Care device makers to platform companies,” said Wayne Woodard, CEO of Argonaut.
The CMO's new offering provides a wide range of solutions including synthetic PCR controls, antibodies, buffers, and markers. Controls and standards can also be lyophilized to both extend shelf-life and improve protocols.
Rather than being restricted to off-the-shelf controls or putting in the capital equipment and labour-intensive SOPs to manufacture their own controls, clients can quickly add controls that are specific for their assays.
Eric Blair, COO of Argonaut, said that with the company's strength in lyophilization, its Custom Molecular Controls and Standards service offers opportunities for improving assays by reducing waste due to shelf-life issues, and simplifying protocols by reducing pipetting and mixing steps.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance